BioMarin Pharmaceutical Inc.
NASDAQBioMarin Pharmaceutical heads into its May 4 Q1 earnings report with short sellers at their most committed in months — a notable shift for a stock where positioning had been relatively relaxed for much of the first quarter. The dominant story this week is the sharp rebuild in short interest. SI climbed from 4.4% of free float in mid-April to 5.25% — a 13% week-on-week increase and…
Snapshot as of 7 May 2026
BioMarin Pharmaceutical heads into its May 4 Q1 earnings report with short sellers at their most committed in months — a notable shift for a stock where positioning had been relatively relaxed for much of the first…
Short sellers ramped up positions ahead of BMRN's Q1 print. Options traders show strong call bias, suggesting near-term bullish sentiment despite the bearish positioning. Short interest stands at 8.97 million shares,…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BMRN — free to start on ORTEX.
Sign up for free →Open BMRN on ORTEX